Introduction
The efficacy of Stereotactic Body Radiation Therapy (SBRT) of the liver is hindered by the inability to accurately localize the lesion at the time of treatment. Liver metastases and the liver parenchyma are iso-attenuating, so these tumors cannot be seen directly with cone-beam CT (CBCT). The image quality of CBCT is also degraded by the large respiratory-induced motion of the abdomen, and it is difficult to visualize the surface of the liver. The lack of direct anatomical landmarks for localization necessitates larger safety margins, which in turn increases the mean dose to the liver and potentially increases the incidence of radiation-induced liver disease [1] .
Despite these difficulties, the unique dual-supply architecture of the liver makes it possible to improve the quality of imaging with IV agents. This concept is exploited in Contrast-Enhanced CT (CECT), and can be used in diagnosis and/or treatment planning to visualize liver metastases [2] . If an image is acquired during venous perfusion of the liver, the parenchyma appears bright while the tumor is unchanged, and thus the lesion can be differentiated from the surrounding tissue. 1 To whom any correspondence should be addressed. in a reduction in noise and a higher SNR for half-fan images. No significant different in SNR was seen when the tube voltage changed from 125 kV to 100 kV. Since the attenuation coefficient for iodine is greater at lower photon energies, there was a larger signal observed in the iodine-loaded samples. However, this increase is offset by a reduction in imaging dose due to the lower bremsstrahlung production efficiency within the photon source of 100 keV electrons (compared to 125 keV). This increased the noise in the images, and resulted in no net SNR change. Fig. 2D demonstrates the effect of total CBCT acquisition time for a 125 mL injection at 3 mL/s. As the scan time increases, a greater portion of the image is taken at a time where either the iodine has not arrived at the liver, or the iodine has washed out of the liver. As a result, the mean iodine concentration in the image decreases and the SNR is reduced. Fig. 2E demonstrates the magnitude of the effects of sub-optimal timing between the initiation of the iodine injection and initiation of the CBCT acquisition. SNR is degraded by as much as 40% if the CBCT acquisition is started at the incorrect time. The degradation is lessened for delays greater than the optimum time; this is due to the fact that iodine washes out of the liver slower than the initial bolus enters, or in other words, the slope of the HEVT curve is lower on the receding side.
Discussion and Conclusions
CE-CBCT takes advantage of the unique architecture of the liver to increase the visibility of hepatic malignancies. This, in turn, facilitates better treatment accuracy in intense therapies such as SBRT that rely on very large dose gradients to spare normal tissue. In order to improve the image quality of CE-CBCT, we have investigated factors which affect the amount of iodine present during imaging, and have developed a model to optimize these parameters. In general, SNR increases as the mean iodine concentration during imaging increases. Increasing the dose of iodine injected has a large effect (up to 100% SNR increase, Fig. 2B ); increasing the rate of injection also plays a role.
Several challenges remain to be addressed before CE-CBCT can be successful clinically. One can optimize the CE-CBCT acquisition for a given HEVT curve, but these curves are known to vary based on patient-specific factors such as weight and cardiac output. Our results indicate that the resulting image quality can be very sensitive to errors in timing, and so it is crucial to know the time to peak enhancement for a given patient. Possible solutions are to use bolus-tracking during the simulation CECT, and record the relative timing during that acquisition, or to acquire liver perfusion images prior to treatment. A more comprehensive way may be to investigate an injection/acquisition protocol which is less sensitive to differences in the time to peak enhancement.
The ultimate goal of this work is to improve the accuracy of liver SBRT. In this preliminary study, we demonstrate techniques to increase the signal-to-noise ratio of CE-CBCT imaging; however, conspicuity of liver lesions can depend on many factors (tumor size, shape of the lesion, SNR, background characteristics, and other factors). The results of this study will be used to guide future clinical implementations of contrast-enhanced CBCT. A pilot study is underway in our department to assess the clinical impact of IV contrast on the visibility of liver lesions and the localization accuracy benefit of this imaging.
